At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
CAP-1002 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)
In Brief
A Phase 2 clinical trial evaluating CAP-1002 and Placebo for Covid19. Completed, enrolled 55 participants across 4 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedNov 10, 2020
Enrollment StartNov 15, 2020
Primary CompletionFeb 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.6 years ago
Interventions
CAP-1002biological
Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)
Placebobiological
Matching placebo solution